Table 1.
Clinicopathological features | Cases | MiR-101-1 expression | P value | ||
---|---|---|---|---|---|
Low | High | ||||
Age | ≥50 | 563 | 291 | 272 | 0.254 |
<50 | 218 | 99 | 119 | ||
Gender | Female | 772 | 382 | 390 | 0.241 |
Male | 9 | 8 | 1 | ||
T | T1–T2 | 657 | 338 | 319 | 0.086 |
T3–T4 | 123 | 52 | 71 | ||
N | N0 | 373 | 183 | 190 | 0.546 |
N1–N3 | 398 | 205 | 193 | ||
M | M0 | 610 | 325 | 285 | 0.298 |
M1 | 9 | 2 | 7 | ||
Stage | I–II | 587 | 290 | 297 | 0.782 |
III–IV | 186 | 94 | 92 | ||
ER | Positive | 565 | 259 | 306 | <0.001 |
Negative | 170 | 111 | 59 | ||
PR | Positive | 502 | 221 | 281 | <0.001 |
Negative | 231 | 148 | 83 | ||
HER2 | Positive | 99 | 57 | 42 | 0.037 |
Negative | 397 | 202 | 195 |
T – tumor stage; N – lymph node stage; M – metastasis stage; ER – estrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor 2. The median was chosen as the cut-off value because of the skewed distribution of the expression data.